Here are the fund managers Morningstar considers the best of the best.
The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.
Stocks dropped Monday after a second weekly loss.
Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."
CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.
European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.
The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?
There are few new cancer drugs to treat kids, and not much research is being done.
Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.
Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.
Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.
Severin Schwan, CEO of Roche Group, says the world was surprised by the "magnitude" of the Ebola outbreak.